NOxGuard – proactive control of nitrosamine risks in pharmaceutical manufacturing
The formation of nitrosamines has become a critical challenge for the pharmaceutical industry in recent years. Since nitrosamines are classified as potentially carcinogenic, regulatory authorities such as the FDA, EMA and WHO have significantly tightened their requirements for risk assessment, monitoring and control. As a result, pharmaceutical manufacturers are increasingly required to implement preventive and transparent measures to minimize the risk of nitrosamine formation throughout their production processes.
With NOxGuard, Glatt has developed an integrated technology concept designed to proactively reduce this risk at its source. NOxGuard focuses on the controlled reduction and monitoring of nitrogen dioxide (NO₂), a key contributor to nitrosamine formation.
The NOxGuard system combines real‑time NO₂ monitoring with intelligent process integration, enabling manufacturers to continuously observe and control critical parameters instead of relying on retrospective testing alone. By making NO₂ levels visible during production, potential risk situations can be identified early and addressed directly within the process.
A central aspect of NOxGuard is its integration into pharmaceutical equipment and process environments. The technology can be implemented in new systems as well as retrofitted into existing installations, allowing manufacturers to respond to regulatory requirements without fundamental changes to their production strategy. This flexibility supports both ongoing compliance and long‑term process robustness.
Beyond regulatory compliance, the system contributes to overall process reliability and transparency. Continuous monitoring helps stabilize production conditions, reduces uncertainty during audits and supports data‑driven decision‑making in pharmaceutical manufacturing environments.
With NOxGuard, Glatt expands its portfolio of safety‑ and compliance‑oriented technologies, reinforcing its focus on integrated solutions that help pharmaceutical manufacturers address emerging challenges in a controlled and future‑ready manner.
